stockrowAlector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024.
- Revenue
- +4,895.9%
- EPS
- +426.5%
- Free cash flow
- +25.7%
- Total debt
- +3.27%
Quarter to September 2026, against a year earlier
Follow ALEC
Alert me
Alector, Inc. (ALEC) EV/Sales
As of 6 November 2026, Alector, Inc. (ALEC) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from −4.2× (January 2026) to 134× (July 2021); the current reading is higher than 50% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −4.1× | — |
| FY2024 | −2.1× | — |
| FY2023 | 1.7× | 172.84% |
| FY2022 | 0.6× | (87.11%) |
| FY2021 | 4.7× | (87.83%) |
| FY2020 | 38.6× | 7.97% |
| FY2019 | 35.8× | — |
| FY2018 | −2.9× | — |
| FY2017 | −2.9× | — |
| FY2016 | −2.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 0.5× | (89.85%) |
| Jun 2026 | 5.0× | 123.14% |
| Mar 2026 | 2.2× | — |
| Dec 2025 | −4.1× | — |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SCTX Scribe Therapeutics Inc. compare | n/m |
| EIKN Eikon Therapeutics, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ALEC Alector, Inc. | 0.8× |
| ENTA Enanta Pharmaceuticals, Inc. compare | 2.0× |
| FENC Adherex Technologies Inc. compare | 5.4× |
| XFOR X4 Pharmaceuticals, Inc. compare | 17.0× |
| PROK ProKidney Corp. compare | 40.7× |
| BNTC Benitec Biopharma Limited compare | 3,500× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)